MatthewKyleLabriolaMD

Oncology • Durham, NC

Matthew Labriola, M.D./Duke University Internal Medicine Resident

Join to view full profile

Dr. Labriola is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Labriola's full profile

Already have an account?

Office
2301 Erwin Rd
Durham, NC 27705
Phone+1 516-448-1521

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 2019 - 2022
Duke University HospitalResidency, Internal Medicine, 2016 - 2020
Duke University HospitalResidency, Internal Medicine, 2017 - 2019
Georgetown University School of MedicineClass of 2016

Certifications & Licensure

NC State Medical License 2016 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

1 citations
DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes.
Laura S Graham, Nicholas C Henderson, Olesia Kellezi, Clara Hwang, Pedro C Barata
JCO Precision Oncology. 2024-08-01
Clinical implications of Wnt pathway genetic alterations in men with advanced prostate cancer.
Amanda Broderick, Elizabeth Pan, Jinju Li, Alec Chu, Clara Hwang
Prostate Cancer and Prostatic Diseases. 2024-07-17
2 citations
Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations.
Joseph J Park, Alec Chu, Jinju Li, Alicia Ali, Rana R McKay
JCO Precision Oncology. 2024-04-01

Lectures

Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic re...
2019 ASCO Annual Meeting - 6/1/2019
Concordance between PD-L1 assays for metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC).
2019 ASCO Annual Meeting - 6/1/2019